Skip to main content
. 2020 Aug 13;5:75. doi: 10.1038/s41541-020-00224-0

Fig. 2. Lymphoproliferation induced by ChimeraT and the specific T-cell epitopes in visceral leishmaniasis patients and healthy subjects.

Fig. 2

PBMC were isolated from VL patients (n = 10) before and after treatment and from healthy subjects (n = 10). Induction of lymphoproliferative response (stimulation index, SI) by ChimeraT was compared to the PHB, EIF5a, LiHyp1 or LiHyp2 synthetic peptides (a), and the corresponding source recombinant proteins and SLA (b). Data are the mean of 10 tested individuals in each group and the error bars denote the standard deviations. (*) indicates statistically significant differences compared to the VL patients before treatment (P < 0.001). Statistics were done using one-way analysis of variance (ANOVA), followed by Bonferroni´s post-test, which was used for multiple comparisons, and P values < 0.05 were considered significant.